Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the EACR 2021 Congress, which will take place from June 9 -12. We’re proud to be able to share this data, which proves the potential of this specific TLR3 agonist in immuno-oncology, in particular by releasing tumor-specific antigens.
Recent Comments